India Daily Briefing

SEBI has initiated a review of its derivatives settlement price methodology following abnormal closing-auction-session (CAS) volatility that distorted F&O expiry pricing in August 2026. Economic Times Markets reported that the proposed change — shifting from CAS-based to volume-weighted average pricing — would directly affect how Nifty and Bank Nifty option settlements are calculated on expiry day. For F&O traders, this is structural: settlement-week gamma strategies, particularly short-strangle setups that rely on predictable expiry-day price anchoring, would need to be recalibrated from October onwards. Mint Markets also confirmed SEBI is soliciting industry comment before the rule takes effect, suggesting an October or November implementation timeline.

Fosun Pharma, the Chinese promoter of Gland Pharma holding approximately 57% post-IPO, is preparing to offload a 5% equity stake through a block deal worth an estimated ₹2,279 Crore — equivalent to roughly 7.85 million shares at current market price. Economic Times Markets reported the deal is likely to be priced at a 3-5% discount to the prevailing CMP to attract institutional buyers, a standard block-deal mechanics that typically resolves within 2-3 sessions when domestic MFs absorb at the discount. This is Fosun's third tranche sale and reduces its India-listed pharma exposure at a time when its own balance sheet is under refinancing pressure in China. Watch the DII absorption rate on Friday — if mutual fund schemes step in quickly at the discount, Gland stabilises; if they pass, the stock tests lower support.

Fed Governor Christopher Waller's 'give disinflation a chance' speech effectively takes a September Fed rate hike off the table, directly reducing the probability of sudden USD strengthening that forces FII rotation out of EM equities. Mint Markets reported US stocks climbed on the comments, confirming markets interpreted Waller's stance as dovish. For Nifty 50, this matters because FII selling pressure (₹2,345 Crore today) was already being absorbed by DII — a dovish Fed maintains that dynamic by keeping INR from depreciating sharply and avoiding the margin-call cascade that hit EM markets in the 2025 rate-hike period. The FCNRB deposit story (Economic Times Markets noted RoE matters more than NIM for banks absorbing NRI inflows) adds another layer: banks with higher FCNRB exposure benefit from NRI inflows at stable INR/USD, making HDFC Bank and ICICI Bank positioned to outperform if the Fed holds.